Cue biopharma reports first quarter 2022 financial results

Boston, may 10, 2022 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted t cells directly within the patient's body, today reported first quarter 2022 financial results. the company will not host a business update call in conjunction with its financial results press release.
CUE Ratings Summary
CUE Quant Ranking